![Elaine Ferguson SFHEA PhD MPharm MRPharmS FAPS](https://profiles-cardiff.imgix.net/attachments/7088?w=200&h=200&auto=format&crop=faces&fit=crop&q=90")
Yr Athro Elaine Ferguson
(hi/ei)
SFHEA PhD MPharm MRPharmS FAPS
- Sylwebydd y cyfryngau
- Ar gael fel goruchwyliwr ôl-raddedig
Timau a rolau for Elaine Ferguson
Athro
Trosolwg
Tissue Engineering & Reparative Dentistry Microbial Effects on Tissue Function, and Tissue Repair and Remodelling Repair and Regeneration in the Oral MucosaResearch Theme
Research Group
Research Interests
Selected Publications
Selected Projects
Cyhoeddiad
2025
- Sharma, P. et al. 2025. The pharmacokinetics of hexylresorcinol-containing lozenges and their antimicrobial efficacy against oral and respiratory microorganisms. Journal of Oral Microbiology 17 (1) 2525229. (10.1080/20002297.2025.2525229)
2024
- Wootton, H. S. et al., 2024. Adaptable synthesis of chondroitin sulfate disaccharide subtypes preprogrammed for regiospecific O-sulfation. European Journal of Organic Chemistry 27 (40) e202400587. (10.1002/ejoc.202400587)
- Rizzo, S. et al. 2024. Modification of the antibiotic, colistin, with dextrin causes enhanced cytotoxicity and triggers apoptosis in myeloid leukemia. International Journal of Nanomedicine 19 , pp.5419-5437. (10.2147/IJN.S449185)
- Varache, M. et al. 2024. Dextrin conjugation to colistin inhibits its toxicity, cellular uptake and acute kidney injury in vivo. RSC Pharmaceutics 1 , pp.68-79. (10.1039/D3PM00014A)
2023
- Sharma, P. et al., 2023. In vitro antibiofilm activity of hexylresorcinol lozenges against oropharyngeal pathogens. Presented at: 2023 ERS International Congress Milan, Italy 9-13 September 2023. European Respiratory Society(10.1183/13993003.congress-2023.PA603)
2022
- Stokniene, J. et al. 2022. Alginate oligosaccharides enhance diffusion and activity of colistin in a mucin-rich environment. Scientific Reports 12 4986. (10.1038/s41598-022-08927-1)
2021
- Chiron, E. et al., 2021. A physicochemical assessment of the thermal stability of dextrin–colistin conjugates. Scientific Reports 11 10600. (10.1038/s41598-021-89946-2)
2020
- Stokniene, J. et al. 2020. Bi-functional alginate oligosaccharide–polymyxin conjugates for improved treatment of multidrug-resistant gram-negative bacterial infections. Pharmaceutics 12 (11) 1080. (10.3390/pharmaceutics12111080)
2019
- Ferguson, E. et al. 2019. Polysaccharides for protein and peptide conjugation. In: Pasut, G. and Zalipsky, S. eds. Polymer-Protein Conjugates: From Pegylation and Beyond. Elsevier. , pp.421-453. (10.1016/B978-0-444-64081-9.00019-X)
- Varache, M. et al. 2019. Polymer masked-unmasked protein therapy: Identification of the active species after amylase-activation of dextrin-colistin conjugates.. Molecular Pharmaceutics 16 (7), pp.3199-3207. (10.1021/acs.molpharmaceut.9b00393)
2018
- Ferguson, E. L. et al. 2018. Controlled release of Dextrin-conjugated growth factors to support growth and differentation of neural stem cells. Stem Cell Research 33 , pp.69-78. (10.1016/j.scr.2018.10.008)
- Powell, L. C. et al. 2018. Targeted disruption of the extracellular polymeric network of pseudomonas aeruginosa biofilms by alginate oligosaccharides. npj Biofilms and Microbiomes 4 13. (10.1038/s41522-018-0056-3)
2017
- Scomparin, A. et al., 2017. Two-step polymer- and liposome- enzyme prodrug therapies for cancer: PDEPT and PELT concepts and future perspectives. Advanced Drug Delivery Reviews 118 , pp.52-64. (10.1016/j.addr.2017.09.011)
- Ferguson, E. L. et al. 2017. HPMA copolymer-phospholipase C and dextrin-phospholipase A2 as model triggers for polymer enzyme liposome therapy (PELT). Journal of drug targeting 25 (9-10), pp.818-828. (10.1080/1061186X.2017.1358726)
- Pritchard, M. F. et al. 2017. The antimicrobial effects of the alginate oligomer OligoG CF-5/20 are independent of direct bacterial cell membrane disruption. Scientific Reports 7 44731. (10.1038/srep44731)
2016
- Roberts, J. L. et al. 2016. In vitro evaluation of the interaction of dextrin-colistin conjugates with bacterial lipopolysaccharide. Journal of Medicinal Chemistry 59 (2), pp.647-654. (10.1021/acs.jmedchem.5b01521)
2015
- Azzopardi, E. A. , Ferguson, E. L. and Thomas, D. W. 2015. Development and validation of an in vitro pharmacokinetic/pharmacodynamic model to test the antibacterial efficacy of antibiotic polymer conjugates. Antimicrobial Agents and Chemotherapy 59 (4), pp.1837-1843. (10.1128/AAC.03708-14)
2014
- Ferguson, E. L. et al. 2014. Dextrin-Colistin conjugates as a model bioresponsive treatment for multidrug resistant bacterial infections. Molecular Pharmaceutics 11 (12), pp.4437-4447. (10.1021/mp500584u)
- Azzopardi, E. A. , Ferguson, E. L. and Thomas, D. W. 2014. A novel class of bioreponsive nanomedicines for localised reinstatement of bioactivity and specific targeting [Abstract]. The Lancet 383 , pp.S9. (10.1016/S0140-6736(14)60272-5)
2013
- Azzopardi, E. A. et al. 2013. Statistical characterization of succinoylated dextrin degradation behavior in human α-amylase. Journal of Carbohydrate Chemistry 32 (7), pp.438-449. (10.1080/07328303.2013.831434)
- Azzopardi, E. A. , Ferguson, E. L. and Thomas, D. W. 2013. Colistin past and future: A bibliographic analysis. Journal of Critical Care 28 (2), pp.219.e13-219.e19. (10.1016/j.jcrc.2012.04.008)
- Azzopardi, E. A. , Ferguson, E. L. and Thomas, D. W. 2013. The enhanced permeability retention effect: a new paradigm for drug targeting in infection. Journal of Antimicrobial Chemotherapy 68 (2), pp.257-274. (10.1093/jac/dks379)
- Naderi, N. et al., 2013. Carbon nanotubes in the diagnosis and treatment of malignant melanoma. Anti-Cancer Agents in Medicinal Chemistry 13 (1), pp.171-185. (10.2174/1871520611307010171)
2011
- Ferguson, E. L. et al. 2011. Evaluation of the physical and biological properties of hyaluronan and hyaluronan fragments. International Journal of Pharmaceutics 420 (1), pp.84-92. (10.1016/j.ijpharm.2011.08.031)
- Izzo, L. et al., 2011. Impact of polymer tacticity on the physico-chemical behaviour of polymers proposed as therapeutics. International Journal of Pharmaceutics 408 (1-2), pp.213-222. (10.1016/j.ijpharm.2011.02.003)
2010
- Ferguson, E. L. , Alshame, A. M. J. and Thomas, D. W. 2010. Evaluation of hyaluronic acid-protein conjugates for polymer masked-unmasked protein therapy. International Journal of Pharmaceutics 402 (1-2), pp.95-102. (10.1016/j.ijpharm.2010.09.029)
- Ferguson, E. L. , Richardson, S. C. W. and Duncan, R. 2010. Studies on the mechanism of action of dextrin-phospholipase A2 and its suitability for use in combination therapy. Molecular Pharmaceutics 7 (2), pp.510-521. (10.1021/mp900232a)
- Ferguson, E. L. et al. 2010. Time-Resolved Small-Angle Neutron Scattering as a Tool for Studying Controlled Release from Liposomes using Polymer-Enzyme Conjugates. Macromolecular Rapid Communications 31 (19), pp.1685-1690. (10.1002/marc.201000241)
2009
- Ferguson, E. L. and Duncan, R. 2009. Dextrin-phospholipase A2: Synthesis and evaluation as a bioresponsive anticancer conjugate. Biomacromolecules 10 (6), pp.1358-1364. (10.1021/bm8013022)
- Treetharnmathurot, B. et al. 2009. Dextrin-trypsin and ST-HPMA-trypsin conjugates: Enzyme activity, autolysis and thermal stability. International Journal of Pharmaceutics 373 (1-2), pp.68-76. (10.1016/j.ijpharm.2009.02.008)
2008
- Hardwicke, J. et al. 2008. Dextrin-rhEGF conjugates as bioresponsive nanomedicines for wound repair. Journal of Controlled Release 130 (3), pp.275-283. (10.1016/j.jconrel.2008.07.023)
- Richardson, S. C. W. et al. 2008. The use of fluorescence microscopy to define polymer localisation to the late endocytic compartments in cells that are targets for drug delivery. Journal of Controlled Release 127 (1), pp.1-11. (10.1016/j.jconrel.2007.12.015)
- Ferguson, E. L. 2008. Bioresponsive polymer-phospholipase A2 conjugates as novel anti-cancer agents. PhD Thesis , Cardiff University.
Adrannau llyfrau
- Ferguson, E. et al. 2019. Polysaccharides for protein and peptide conjugation. In: Pasut, G. and Zalipsky, S. eds. Polymer-Protein Conjugates: From Pegylation and Beyond. Elsevier. , pp.421-453. (10.1016/B978-0-444-64081-9.00019-X)
Cynadleddau
- Sharma, P. et al., 2023. In vitro antibiofilm activity of hexylresorcinol lozenges against oropharyngeal pathogens. Presented at: 2023 ERS International Congress Milan, Italy 9-13 September 2023. European Respiratory Society(10.1183/13993003.congress-2023.PA603)
Erthyglau
- Sharma, P. et al. 2025. The pharmacokinetics of hexylresorcinol-containing lozenges and their antimicrobial efficacy against oral and respiratory microorganisms. Journal of Oral Microbiology 17 (1) 2525229. (10.1080/20002297.2025.2525229)
- Wootton, H. S. et al., 2024. Adaptable synthesis of chondroitin sulfate disaccharide subtypes preprogrammed for regiospecific O-sulfation. European Journal of Organic Chemistry 27 (40) e202400587. (10.1002/ejoc.202400587)
- Rizzo, S. et al. 2024. Modification of the antibiotic, colistin, with dextrin causes enhanced cytotoxicity and triggers apoptosis in myeloid leukemia. International Journal of Nanomedicine 19 , pp.5419-5437. (10.2147/IJN.S449185)
- Varache, M. et al. 2024. Dextrin conjugation to colistin inhibits its toxicity, cellular uptake and acute kidney injury in vivo. RSC Pharmaceutics 1 , pp.68-79. (10.1039/D3PM00014A)
- Stokniene, J. et al. 2022. Alginate oligosaccharides enhance diffusion and activity of colistin in a mucin-rich environment. Scientific Reports 12 4986. (10.1038/s41598-022-08927-1)
- Chiron, E. et al., 2021. A physicochemical assessment of the thermal stability of dextrin–colistin conjugates. Scientific Reports 11 10600. (10.1038/s41598-021-89946-2)
- Stokniene, J. et al. 2020. Bi-functional alginate oligosaccharide–polymyxin conjugates for improved treatment of multidrug-resistant gram-negative bacterial infections. Pharmaceutics 12 (11) 1080. (10.3390/pharmaceutics12111080)
- Varache, M. et al. 2019. Polymer masked-unmasked protein therapy: Identification of the active species after amylase-activation of dextrin-colistin conjugates.. Molecular Pharmaceutics 16 (7), pp.3199-3207. (10.1021/acs.molpharmaceut.9b00393)
- Ferguson, E. L. et al. 2018. Controlled release of Dextrin-conjugated growth factors to support growth and differentation of neural stem cells. Stem Cell Research 33 , pp.69-78. (10.1016/j.scr.2018.10.008)
- Powell, L. C. et al. 2018. Targeted disruption of the extracellular polymeric network of pseudomonas aeruginosa biofilms by alginate oligosaccharides. npj Biofilms and Microbiomes 4 13. (10.1038/s41522-018-0056-3)
- Scomparin, A. et al., 2017. Two-step polymer- and liposome- enzyme prodrug therapies for cancer: PDEPT and PELT concepts and future perspectives. Advanced Drug Delivery Reviews 118 , pp.52-64. (10.1016/j.addr.2017.09.011)
- Ferguson, E. L. et al. 2017. HPMA copolymer-phospholipase C and dextrin-phospholipase A2 as model triggers for polymer enzyme liposome therapy (PELT). Journal of drug targeting 25 (9-10), pp.818-828. (10.1080/1061186X.2017.1358726)
- Pritchard, M. F. et al. 2017. The antimicrobial effects of the alginate oligomer OligoG CF-5/20 are independent of direct bacterial cell membrane disruption. Scientific Reports 7 44731. (10.1038/srep44731)
- Roberts, J. L. et al. 2016. In vitro evaluation of the interaction of dextrin-colistin conjugates with bacterial lipopolysaccharide. Journal of Medicinal Chemistry 59 (2), pp.647-654. (10.1021/acs.jmedchem.5b01521)
- Azzopardi, E. A. , Ferguson, E. L. and Thomas, D. W. 2015. Development and validation of an in vitro pharmacokinetic/pharmacodynamic model to test the antibacterial efficacy of antibiotic polymer conjugates. Antimicrobial Agents and Chemotherapy 59 (4), pp.1837-1843. (10.1128/AAC.03708-14)
- Ferguson, E. L. et al. 2014. Dextrin-Colistin conjugates as a model bioresponsive treatment for multidrug resistant bacterial infections. Molecular Pharmaceutics 11 (12), pp.4437-4447. (10.1021/mp500584u)
- Azzopardi, E. A. , Ferguson, E. L. and Thomas, D. W. 2014. A novel class of bioreponsive nanomedicines for localised reinstatement of bioactivity and specific targeting [Abstract]. The Lancet 383 , pp.S9. (10.1016/S0140-6736(14)60272-5)
- Azzopardi, E. A. et al. 2013. Statistical characterization of succinoylated dextrin degradation behavior in human α-amylase. Journal of Carbohydrate Chemistry 32 (7), pp.438-449. (10.1080/07328303.2013.831434)
- Azzopardi, E. A. , Ferguson, E. L. and Thomas, D. W. 2013. Colistin past and future: A bibliographic analysis. Journal of Critical Care 28 (2), pp.219.e13-219.e19. (10.1016/j.jcrc.2012.04.008)
- Azzopardi, E. A. , Ferguson, E. L. and Thomas, D. W. 2013. The enhanced permeability retention effect: a new paradigm for drug targeting in infection. Journal of Antimicrobial Chemotherapy 68 (2), pp.257-274. (10.1093/jac/dks379)
- Naderi, N. et al., 2013. Carbon nanotubes in the diagnosis and treatment of malignant melanoma. Anti-Cancer Agents in Medicinal Chemistry 13 (1), pp.171-185. (10.2174/1871520611307010171)
- Ferguson, E. L. et al. 2011. Evaluation of the physical and biological properties of hyaluronan and hyaluronan fragments. International Journal of Pharmaceutics 420 (1), pp.84-92. (10.1016/j.ijpharm.2011.08.031)
- Izzo, L. et al., 2011. Impact of polymer tacticity on the physico-chemical behaviour of polymers proposed as therapeutics. International Journal of Pharmaceutics 408 (1-2), pp.213-222. (10.1016/j.ijpharm.2011.02.003)
- Ferguson, E. L. , Alshame, A. M. J. and Thomas, D. W. 2010. Evaluation of hyaluronic acid-protein conjugates for polymer masked-unmasked protein therapy. International Journal of Pharmaceutics 402 (1-2), pp.95-102. (10.1016/j.ijpharm.2010.09.029)
- Ferguson, E. L. , Richardson, S. C. W. and Duncan, R. 2010. Studies on the mechanism of action of dextrin-phospholipase A2 and its suitability for use in combination therapy. Molecular Pharmaceutics 7 (2), pp.510-521. (10.1021/mp900232a)
- Ferguson, E. L. et al. 2010. Time-Resolved Small-Angle Neutron Scattering as a Tool for Studying Controlled Release from Liposomes using Polymer-Enzyme Conjugates. Macromolecular Rapid Communications 31 (19), pp.1685-1690. (10.1002/marc.201000241)
- Ferguson, E. L. and Duncan, R. 2009. Dextrin-phospholipase A2: Synthesis and evaluation as a bioresponsive anticancer conjugate. Biomacromolecules 10 (6), pp.1358-1364. (10.1021/bm8013022)
- Treetharnmathurot, B. et al. 2009. Dextrin-trypsin and ST-HPMA-trypsin conjugates: Enzyme activity, autolysis and thermal stability. International Journal of Pharmaceutics 373 (1-2), pp.68-76. (10.1016/j.ijpharm.2009.02.008)
- Hardwicke, J. et al. 2008. Dextrin-rhEGF conjugates as bioresponsive nanomedicines for wound repair. Journal of Controlled Release 130 (3), pp.275-283. (10.1016/j.jconrel.2008.07.023)
- Richardson, S. C. W. et al. 2008. The use of fluorescence microscopy to define polymer localisation to the late endocytic compartments in cells that are targets for drug delivery. Journal of Controlled Release 127 (1), pp.1-11. (10.1016/j.jconrel.2007.12.015)
Gosodiad
- Ferguson, E. L. 2008. Bioresponsive polymer-phospholipase A2 conjugates as novel anti-cancer agents. PhD Thesis , Cardiff University.
Ymchwil
Mae fy ymchwil gyfredol yn canolbwyntio ar ddatblygu cyfuniadau polymer sy'n ymateb i ensymau uwch sy'n ymateb i amrywiad ffisiolegol a patholegol mewn gweithgaredd ensym i sbarduno rhyddhau llwyth tâl bioactif. Mae fy ymchwil a gyhoeddwyd yn ddiweddar ac a ariennir ar hyn o bryd wedi dangos potensial cyfuniadau polymer sy'n seiliedig ar polysacarid i gyflawni rhyddhau cyffuriau safle-benodol (yn seiliedig ar weithgaredd ensym cynyddol ar safleoedd llid, e.e., canser a haint). Dangoswyd potensial y dulliau therapiwtig hyn i leihau sgîl-effeithiau (ee, nephrotoxicity) a gwella gweithgaredd biolegol y cyffur rhiant. Nod gwaith parhaus yw optimeiddio dyluniad y cyfuniadau polymer sy'n ymateb i ensymau hyn i wneud y mwyaf o'u potensial clinigol.
Prosiectau Cyfredol
Cyfuniadau polymer-cyffuriau dwy-swyddogaethol ar gyfer atal a thrin atherosglerosis. Nod: Optimeiddio dyluniad rhesymegol, synthesis a chyflenwi cyfuniadau polymer-cyffuriau, nodi cyfansoddyn arweiniol ar gyfer profion clinigol a datblygiad masnachol ar raddfa lawn.
Ymchwilio i effaith rhythmau circadaidd ar therapiwteg polymer. Anelu: Ymchwilio i sut mae rhythmau circadaidd naturiol y corff yn dylanwadu ar ddosbarthiad, defnydd cellog ac effeithiolrwydd therapiwteg polymer.
Cludwyr cyflenwi cyffuriau newydd sy'n seiliedig ar polysacaridau ar gyfer therapiwteg polymer Nod: Archwilio potensial ffynonellau a strwythurau amgen polysacaridau biolegol actif fel cludwyr newydd ar gyfer cyffuriau protein a peptid.
Datblygu modelau in vitro i astudio patrymau rhyddhau cyffuriau systemau cyflenwi cyffuriau bioymatebol
Anelu: Nodweddu patrymau rhyddhau cyffuriau ac effeithiau ffarmacolegol amser real o gyfuniadau polymer bioymatebol mewn amgylcheddau ffisiolegol efelychu.
Cyllid
- 2025: Cyllid Diwylliant Ymchwil Prifysgol Caerdydd: 'Digwyddiadau adeiladu cymunedol Uned Asesu 3' (£1,857, ymgeisydd arweiniol).
- 2025: Gwobr Cyflymu Effaith MRC Cronfa ddilynol: 'Gwella dyluniad polymer-conjugate i wella effeithiolrwydd cyflenwi cyffuriau wrth drin osteoarthritis' (£19,455, cyd-brif ymchwilydd).
- 2025: Dyfarniad Cyflymu Effaith MRC Cronfa ddilynol: Teitl wedi'i ddal yn ôl (£20,000, prif ymchwilydd).
- 2024-2025: Gwobr Offer Craidd EPSRC: 'Galwad Offer EPSRC 2024: Prifysgol Caerdydd' (£300,000, cyd-ymchwilydd).
- 2024: Cyllid Diwylliant Ymchwil Prifysgol Caerdydd: 'Digwyddiad Dangos a Dweud Uned 3' (£2931, prif ymgeisydd).
- 2023-2024: Gwobr Cyflymu Effaith MRC: 'Ail-bwrpasu cyfuniadau dextrin-colistin i atal llid aberrant mewn osteoarthritis' (£43,437, cyd-brif ymchwilydd).
- 2023-2024: Gwobr Offer Craidd EPSRC (EP/X034739/1): 'Galwad Offer EPSRC 2022: Prifysgol Caerdydd' (£457,080, cyd-ymchwilydd).
- 2022-2024: EPSRC Gorwelion Newydd (EP/X019136/1): 'Peirianneg biopolymerau bioymatebol y genhedlaeth nesaf: proteoglycans cartilag dynwared' (£196,228, cyd-ymchwilydd).
- 2022-2025: Llywodraeth Saudi Arabia (ysgoloriaeth PhD): (£125,850, prif ymchwilydd).
- 2022: Ymddiriedolaeth Wellcome (Cyfrif Prosiect Cyfieithu Sefydliadol): 'Datblygu dull nanofeddygaeth i leihau sgîl-effeithiau annerbyniol bexarotene' (£24,831, cyd-ymchwilydd).
- 2020-2022: Y Cyngor Ymchwil Feddygol (Hyder mewn Cysyniad): 'Potential of lactobacillus spp.-derived polysaccharides as novel bi-functional carriers in polymer conjugates' (£53,468, prif ymchwilydd).
- 2020-2021: Ymddiriedolaeth Wellcome (Cronfa Cymorth Strategol Sefydliadol Ailgysylltu â Gwyddoniaeth): 'Development of bio-triggered nanoparticle-antibiotic conjugates to target cancer: impact of modification on cytotoxicity and epigenetic related pathways' (£76,855, noddwr ymchwil).
- 2019: EPSRC ECR Institutional Equipment: 'Contact angle goniometer and quartz crystal microbalance' (£48,000, cyd-ymchwilydd).
- 2018-2022: Cyngor Ymchwil Norwy (281920): 'Cynhyrchion oligomer alginad newydd ar gyfer cyflenwi fferyllol gwell ar draws rhwystr mwcosaidd (Mucos-ALG)' (£297,397, cyd-ymchwilydd).
- 2018-2019: Grant ymchwil y Gymdeithas Frenhinol (RG\R2\180069): 'Datblygu dull ar gyfer dadansoddi ffisiocemegol o sacaridau o gyfuniadau peptid ploysacarid' (£17,986.80, prif ymchwilydd).
- 2018-2019: Gwobr Kickstart Trosiadol ISSF3 Ymddiriedolaeth Wellcome: Datblygu dull nanofeddygaeth ar gyfer targedu canser a heintiau bacteriol ar yr un pryd' (£49,645, prif ymchwilydd).
- 2016-2021: Grant Ymchwil Ymchwilydd Newydd MRC (MR/N023633/1): 'Accumulation and nephrotoxicity of dextrin-colistin conjugates' (£406,496, prif ymchwilydd).
- 2013-2013: Grŵp Datblygu Ymchwil Microbioleg a Heintiau (MITReG) grant Grŵp Datblygu Ymchwil: "Dulliau nanowrthfiotig o gyflwyno gwrthfiotigau" (£4,000, prif ymchwilydd).
- 2012: Grant EPSRC (EP/K031635/1): 'Eitemau bach o offer ymchwil ym Mhrifysgol Caerdydd' (£498,293, cyd-ymchwilydd).
- 2012: Astudiaeth SANS yng nghyfleuster ILL: 'Ymchwilio i gydffurfiad datrysiad a mecanwaith gweithredu oligosacaridau alginad gwrthficrobaidd (OligoG)' (£19,699, prif ymchwilydd).
- 2011: Astudiaeth SANS yn y cyfleuster ILL: 'Novel polymer-antimicrobial conjugates; eu cydffurfiad datrysiad, ymddygiad hunan-gysylltiad a rhyngweithio â lipopolysacaridau' (£19,172, cyd-ymchwilydd).
- 2010-2011: Gwobr Gwerth mewn Pobl Ymddiriedolaeth Wellcome (£41,000 wedi'i ddyfarnu, prif ymchwilydd).
- 2009-2010: Cynllun Cyllido Llwybr Datblygiadol MRC: 'Bioresponsive polymer-peptide conjugates as novel antibacterial agents' (£27,000 wedi'i ddyfarnu, prif ymchwilydd).
- 2008: Astudiaeth SANS yng nghyfleuster ISIS: 'Ymchwilio i Dextrin-Phospholipase A2 Conjugate fel Sbardun ar gyfer Therapi Liposom Ensym Polymer (PELT)' (dyfarnwyd £22,120, prif ymchwilydd).
- 2008: Astudiaeth SANS yng nghyfleuster ISIS: 'Structured Characterisation of a Series of Polymer-Protein Conjugates for Chronic Wound Treatments' (£10,870, cyd-ymchwilydd).
Patentau
- Ferguson E, Thomas DW, Dessen A, Rye P (2016) Conjugates oligomer Bacitracin-alginate. GB201617862. D0.
- Ferguson E, Thomas DW, Dessen A, Rye P (2017) Conjugates oligomer polymyxin-alginate. GB201617860D0, GB201714710D0.
- Ferguson EL, Thomas DW, Walsh T (2012) Conjugates therapiwtig. GB201010500D0, EP2585114B1, ES2523507T3, US8835380B2.
ID ORCID: orcid.org/0000-0002-0125-0234
Comisiynau Ymddiriedaeth
- 2025 - 2025 - cyfredol: Coleg Talent y Dyfodol UKRI, aelod o'r panel.
- 2024 - cyfredol: Cyfnewidfeydd Staff MSCA Horizon Europe, Gwlad Belg, gwerthuswr arbenigol ac aelod o'r panel
- 2023 - 2024: Coleg Asesu Rhyngddisgyblaethol UKRI, aelod o'r panel
- 2021 - 2023 - cyfredol: Cadeirydd, Grŵp Ffocws Nanofeddygaeth - Academi'r Gwyddorau Fferyllol
- 2019 - 2024: Golygydd Cyswllt, Cyflenwi Cyffuriau Seiliedig ar Nano - Ffiniau mewn Technoleg Feddygol
- 2019 - 2019 - 2024: Aelod o'r bwrdd golygyddol, Adroddiadau Gwyddonol
Addysgu
|
Blwyddyn o/i |
Teitl y modiwl/cwrs |
Lefel astudio (e.e. blwyddyn 1) |
Rôl |
|
2023 - presennol |
Addysg ryngbroffesiynol |
Blynyddoedd 1-5 |
Arweinydd pwnc |
|
2018 - 2024 |
MSc mewn Peirianneg Meinwe |
Meistr (wedi'i ddysgu) |
Dirprwy gyfarwyddwr rhaglen |
|
2017 - presennol |
Addysg ryngbroffesiynol |
Blynyddoedd 1 a 2 |
Arweinydd y cwrs a'r hwylusydd |
|
2017 - presennol
|
DET068 (atgyweirio meinwe, adfywio a dulliau gwyddonol) |
Meistr (wedi'i ddysgu)
|
Darlithydd ac arholwr
|
|
2013 - 2023
|
DET002 (Peirianneg meinwe: o'r cysyniad i ymarfer clinigol) |
Meistr (wedi'i ddysgu)
|
Arweinydd y modiwl |
|
2013 - presennol
|
Prosiectau ymchwil blwyddyn olaf, Deintyddfa (BDS) |
Blwyddyn 45 |
Goruchwyliwr prosiect
|
|
2012 - presennol |
Cyflwyniadau PowerPoint, BDS |
Blwyddyn 3 |
Arholwr
|
|
2012 - presennol |
Prosiect poster, BDS |
Blwyddyn 2 |
Arholwr |
|
2012 – presennol |
Proffesiynoldeb viva, BDS |
Blwyddyn 1
|
Arholwr
|
|
2012 – presennol |
Traethawd estynedig, BDS |
Blwyddyn 2 |
Arholwr |
|
2009 – presennol
|
DET028 (Bioleg Cellog a Moleciwlaidd) MSc mewn Mewnblaneg |
Meistr (wedi'i ddysgu)
|
Darlithydd ac arholwr
|
|
2009 - presennol |
DET002 (Peirianneg meinwe: o'r cysyniad i ymarfer clinigol) |
Meistr (wedi'i ddysgu) |
Darlithydd ac arholwr |
Cymwysterau
- 2019: Uwch Gymrawd yr Academi Addysg Uwch
- 2014: Cymrodyr, Academi Addysg Uwch
Bywgraffiad
Graddiais o Brifysgol Manceinion gyda gradd Meistr Fferylliaeth dosbarth cyntaf, ar ôl ennill gwybodaeth eang o egwyddorion a thechnegau gwyddorau fferyllol. Arweiniodd hyn fi i weithio yn y sector diwydiant fferyllol (AstraZeneca) lle caffais brofiad ymarferol o'r sgiliau hyn. Ar ôl cymhwyso fel fferyllydd cofrestredig, penderfynais ddilyn fy niddordeb cynyddol mewn datblygu systemau cyflenwi cyffuriau newydd gan fod fy mhrofiadau fferylliaeth glinigol wedi tynnu sylw at yr angen clinigol am driniaethau newydd. Cwblheais PhD gyda'r Athro Ruth Duncan ym Mhrifysgol Caerdydd yn 2008, lle datblygais gyfuniad polymer-ffosffolipase bioymatebol ar gyfer trin canser y fron. Mae'r ymchwil hon yn 'cadarnhau' fy niddordeb hirsefydlog mewn defnyddio polymerau bioddiraddadwy naturiol fel cludwyr newydd ar gyfer asiantau bioactif.
Ar ôl dangos dichonoldeb therapiwteg polymer bioymatebol mewn canser, canolbwyntiodd fy niddordebau ar archwilio cymwysiadau clinigol newydd. Ar ôl nodi meddygaeth adfywiol fel maes lle gallai conjugates polymer bioymatebol fod â photensial mawr, ymunais â chonsortiwm rhyngddisgyblaethol EPSRC Nanomedicine Platform. Gan ddefnyddio technegau dadansoddol soffistigedig iawn i ddatblygu a phrofi cyfuniadau ffactor twf dextrin, fe wnaethom ddatblygu'r therapiwteg polymer cyntaf ar gyfer atgyweirio meinwe.
Yn fwy diweddar, fe wnaeth fy nghyllid gan MRC ac Ymddiriedolaeth Wellcome alluogi fy ngrŵp i ddylunio a chyflawni'r 'nanowrthfiotig' bioymatebol cyntaf yn seiliedig ar gyfuniadau dextrin-colistin, sy'n dangos gwell sefydlogrwydd cyffuriau, ffarmacocineteg a chadw gweithgaredd gwrthficrobaidd. Mae'r cyllid hwn wedi cefnogi'r gwaith o ddatblygu consortiwm bach, dan arweiniad fi, o glinigwyr, ôl-raddedigion a chynorthwyydd ymchwil, ac wedi denu cyllid pellach, gan gynnwys Grant Ymchwil Ymchwilwyr Newydd MRC a chan Ymddiriedolaeth Wellcome i archwilio targedu canser a heintiau bacteriol ar yr un pryd gyda'n nanowrthfiotig. Fy ymchwil gyfredol yw datblygu therapiwteg polymer sy'n ymateb i ensymau ar gyfer ystod o dargedau newydd a chymwysiadau clinigol newydd.
Cefais fy mhenodi'n Ddarlithydd Therapiwteg Polymer ym mis Ionawr 2013, a'm dyrchafu'n Uwch Ddarlithydd ym mis Awst 2017. Fe wnes i gais yn llwyddiannus am ddyrchafiad i Reader ym mis Awst 2020. Cefais fy mhenodi'n Gyfarwyddwr Ymchwil ar gyfer yr Ysgol Ddeintyddiaeth ym mis Awst 2021. Cefais fy dyrchafu'n Gadeirydd ym mis Awst 2024.
Cyfleoedd PhD ar un o'r pynciau canlynol:
a. Therapiwteg polymer sy'n ymateb i ensymau uwch ar gyfer meddygaeth adfywiol, therapïau canser a gwrth-heintus
b. Datblygu a nodweddu nanowrthfiotigau (gan gynnwys diogelwch ac effaith ar ddatblygu ymwrthedd gwrthficrobaidd)
c. Manteisio ar y microamgylchedd meinwe (canser, haint, llid) mewn therapi
Anrhydeddau a dyfarniadau
- Jun 2016: Poster prize. Cardiff and Vale UHB International Clinical Trials Conference. Cardiff, UK (3rd prize awarded).
- Jun 2015: Poster prize. Cardiff and Vale UHB Research and Development Conference. Cardiff, UK (3rd prize awarded).
- May 2014: Oral presentation. 10th International Symposium on Polymer Therapeutics: From Laboratory to Clinical Practice. Valencia, Spain (2nd prize awarded).
- Dec 2012: Competitive travel grant. Microbiology and Infection Translational Research Group (MITReG) (£400).
- May 2011: Science team award for ‘Best Interdisciplinary Dynamics’, SARTRE Science Showcase. Newport, UK.
- Nov 2010: Oral presentation. Association of British Academic Oral and Maxillofacial Surgeons Annual Meeting. Cardiff, UK (1st prize awarded).
- 2007: Competitive travel grants. Merck Sharp & Dohme (£500), Controlled Release Society ($125).
- Jun ’06: Oral presentation. Highlights of student posters, 33rd Annual Meeting and Exposition of the Controlled Release Society. Vienna, Austria (1st prize awarded).
- 2006: Competitive travel grants. Graduate School of Biomedical and Life Sciences travel grant (£300), Thomas Morgan travel grant (£200).
- Apr 2004: Poster prize. Postgraduate research day, Welsh School of Pharmacy. Cardiff, UK (1st prize awarded).
- 8 prizes awarded to PhD students under my supervision.
Aelodaethau proffesiynol
Royal Pharmaceutical Society (RPS)General Pharmaceutical Council (GPhC)
Cardiff Institute for Tissue Engineering & Repair (CITER)
Microbiology and Infection Translational Research Group (MITReG)European Society of Clinical Microbiology and Infectious Diseases (ESCMID)
British Society of Antimicrobial Chemotherapy (BSAC)
Safleoedd academaidd blaenorol
- Jan 2012 - Jul 2017: Lecturer in Polymer Therapeutics, School of Dentistry, Cardiff, UK.
- Nov 2008 - Dec 2012: Research Associate in Polymer Therapeutics, School of Dentistry, Cardiff, UK.
- May 2008 - Oct 2008: Postdoctoral Research Scientist (Nanomedicines EPSRC Platform Grant), Schools of Chemistry and Pharmacy, Cardiff, UK.
Pwyllgorau ac adolygu
INSTITUTIONAL RESPONSIBILITIES
- 2021 - present: Director of Research (Dentistry), Cardiff University, UK
- 2018 - present: Impact Lead (UoA3), Cardiff University, UK
- 2018 - present: Senior Management Committee (Dentistry), Cardiff University, UK
- 2016 - present: Wellcome Trust ISSF3 grant panel member, Cardiff University, UK
- 2016 - present: Research Committee (Dentistry), Cardiff University, UK
- 2015 - 2016: Enterprise, Engagement and Impact Committee (Dentistry), Cardiff University, UK
- 2014 - present: Postgraduate Research Admissions and Monitoring Committee (Dentistry), Cardiff University, UK
- 2014 - present: Impact and Innovation Committee (College of Biological and Life Sciences), Cardiff University, UK
- 2014 -present: Impact Lead (Dentistry), Cardiff University, UK
- 2013 - 2017: Research Ethics Committee (Dentistry), Cardiff University, UK
- 2012 - 2018: People, Equality and Diversity Committee (Dentistry), Cardiff University, UK
COMMISSIONS OF TRUST
- 2019 - present: Associate Editor, Nano-Based Drug Delivery - Frontiers in Medical Technology
- 2019 - present: Editorial board member, Scientific Reports
- 2019: External examiner, Monash University
- 2018: External examiner, University of Strathclyde
- 2016 - present: Chair of PhD examination panel (x2), Cardiff University, UK
- 2011 - present: Grant reviewing: BBSRC, EPSRC, MRC, UKRI, Wellcome Trust and British Society for Antimicrobial Chemotherapy
- 2010 - present: Reviewer for over 20 journals, e.g.: Nature, Biomacromolecules, Nanomedicine: Nanotechnology, Biology, and Medicine, PLoS ONE, International Journal of Nanomedicine, Journal of the American Chemical Society, Macromolecular Bioscience
Meysydd goruchwyliaeth
I am interested in supervising PhD students in the areas of:
- Polymer therapeutics
- Drug delivery
- Nanomedicine
- Antimicrobial resistance
Goruchwyliaeth gyfredol
Ghaida Almuthri Almuthri
Emma Wright
Burhan Anis
Prosiectau'r gorffennol
- Stokniene, Joana 2019. Dylunio a chydosod oligosacaridau wedi'u teilwra fel therapiwteg polymer ar gyfer gwell triniaeth clefyd anadlol cronig. Goruchwyliwr arweiniol
- Azzopardi, Ernest Anthony 2013. Mae dextrin-colistin bioymatebol yn cyfuno fel asiantau gwrthficrobaidd ar gyfer trin haint Gram-negyddol. Cyd-oruchwyliwr
Contact Details
+44 29225 10663
Ysbyty Deintyddol y Brifysgol, Llawr 1, Ystafell 130, Parc y Mynydd Bychan, Caerdydd, CF14 4XY
Adeilad Redwood , Llawr 2, Ystafell Tŵr T.13, Rhodfa'r Brenin Edward VII, Caerdydd, CF10 3NB
Themâu ymchwil
Arbenigeddau
- Nanofeddygaeth
- Cyflwyno cyffuriau
- Therapiwteg polymer
- Nodweddiad ffysicocemegol
- Cemeg ddadansoddol